A comparative study on safety & efficacy of travoprost & brimonidine/timolol fixed combination in patients of primary open angle Glaucoma at ophthalmology department of Peoples College of Medical Sciences & Research Centre BhanpurBhopal.

•Glaucoma--------Second leading cause of blindness, silent thief of sight.

•   Progressive optic neuropathy with degeneration of

retinal ganglion cells.

•   Irreversible blindness if left undiagnosed & untreated

•   Normal IOP ® 10-20mm Hg.

•

Data from the Early Manifest Glaucoma Trial (EMGT) have shown that an additional 1 mm Hg of IOP lowering reduces the risk of glaucoma progression by 10 %.•At the baseline visit, patients will be randomized into 2 groups after investigations and diagnosis•12.3% of total blindness

•

•Vision loss range from 5.2 to 6.7 million

•

•Prevalence-1% to 4% in people over 40yrs in Asia

•

•¯ in IOP delays damage to optic nerve & visual field

•

•¯ in IOP by 30% ¯ disease progression from ~35 to 10%   .

Travoprost is will be given to one group

& Brimonidine + timolol  to another group

• Follow-up to be done - at 2, 4, 12 wks.

•IOP measurement & fundus examination will be done at every visit.

•Perimetery will be repeated  monthly.